<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522375</url>
  </required_header>
  <id_info>
    <org_study_id>FP045C-19-001</org_study_id>
    <nct_id>NCT04522375</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of FP-045 in Patients With Fanconi Anemia</brief_title>
  <official_title>A Phase 1/2 Multicenter, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of FP-045 in Patients With Fanconi Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foresee Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Foresee Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 dose escalation in adolescents (ages 12-18 y.o.). Once safety established, dose&#xD;
      escalation in pediatric subjects (3-11 y.o.) will follow. In expansion phase 20 adolescent or&#xD;
      pediatric subjects will receive FP-045 at recommended phase 2 dose for 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Phase 1, 3 cohorts of 3 adolescent subjects each will receive one of 3 escalating dose&#xD;
      levels of FP-045 for 28 days to determine safety and tolerability. Once safety evaluation at&#xD;
      highest dose is complete, 3 cohorts of 6 pediatric subjects will receive one of 3 escalating&#xD;
      dose levels of FP-045 to determine safety and tolerability. Subjects tolerating FP-045 well&#xD;
      may go on to receive a total of 3 months of treatment.&#xD;
&#xD;
      In expansion, 20 additional subjects, adolescent and pediatric, will be enrolled and treated&#xD;
      at the recommended phase 2 dose of FP-045 for their age group, for up to 6 months to study&#xD;
      effects on hematologic parameters. All subjects will be followed closely with serial&#xD;
      hematology and chemistry laboratory assessments, physical exams, and monitoring for adverse&#xD;
      events. Samples for pharmacokinetics will be obtained, and multiple pharmacodynamic markers&#xD;
      will be assessed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase 1 dose escalation followed by Phase 2 expanion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase 2 dose of FP-045</measure>
    <time_frame>28 days</time_frame>
    <description>The MTD of FP-045 in adolescent and pediatric subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preliminary activity</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in hemoglobin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>3-6 months</time_frame>
    <description>Frequency of adverse events and serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic profile</measure>
    <time_frame>3- 6 months</time_frame>
    <description>Mean AUC of FP-045 by dose level</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Fanconi Anemia</condition>
  <arm_group>
    <arm_group_label>FP-045</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FP-045 at one of 3 dose levels to sequential cohorts of adolescent, followed by pediatric subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FP-045</intervention_name>
    <description>activator of aldehyde dehydrogenase</description>
    <arm_group_label>FP-045</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female aged 3-18&#xD;
&#xD;
          -  documented Fanconi anemia by chromosome breakage analysis&#xD;
&#xD;
          -  females of child-bearing potential and males required to use highly effective birth&#xD;
             control&#xD;
&#xD;
        Phase 2 only:&#xD;
&#xD;
          -  mild to moderate bone marrow failure with at least one cytopenia of &gt; grade 1 severity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of any malignancy except focal squamous cell or basal cell carcinoma of the&#xD;
             skin or carcinoma in situ of cervix&#xD;
&#xD;
          -  has myelodysplastic syndrome or acute leukemia per world health organization (WHO)&#xD;
             criteria&#xD;
&#xD;
          -  has history of any significant medical conditions&#xD;
&#xD;
          -  has aspartate aminotransferase (AST)/alanine aminotransferase (ALT) &gt; 5x upper limit&#xD;
             of normal (ULN) or calculated creatinine clearance (Clcr) of &lt; 50 mL/min&#xD;
&#xD;
          -  has active Hepatitis B or C&#xD;
&#xD;
          -  has an ongoing systemic infection&#xD;
&#xD;
          -  requires a strong CYP3A4 inhibitor&#xD;
&#xD;
          -  has had major surgery within 30 days&#xD;
&#xD;
        Phase 1:&#xD;
&#xD;
          -  Stem cell or bone marrow transplant within 3 months prior&#xD;
&#xD;
          -  Active graft versus host disease requiring systemic treatment&#xD;
&#xD;
        Phase 2:&#xD;
&#xD;
          -  Has a history of bone marrow or stem cell transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Lau, PHD</last_name>
    <phone>650-518-9886</phone>
    <email>David.Lau@foreseepharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ann Lowe, MD</last_name>
    <phone>512-502-5353</phone>
    <email>amlowe@earthlink.net</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

